This article was originally published in The Gray Sheet
Next-generation vascular closure device gains FDA market go-ahead for use in minimally invasive closure of femoral artery access sites following diagnostic procedures such as coronary angioplasty. Made by Abbott's newly acquired Perclose unit, the Closer takes "less than half the time" of current Perclose closure devices
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.